News – Page 592 – Endpoints News

J&J bets $40M cash on biotech's ADC tech and its battle-tested CEO — with biobucks adding to $1B

4 years ago

Al Sandrock makes his first post-Biogen move, joining turnaround effort at a troubled gene therapy startup

4 years ago

J&J takes a $610M hit as top PhIII prospect goes up in flames after atopic dermatitis study fails

4 years ago

SoftBank leads $150M round into Dewpoint as condensate biotech nears clinic

4 years ago

Exclusive: The curious case of the BioNTech priority review voucher

4 years ago

UPenn sues Genentech over patent infringement with four cancer drugs

4 years ago

That partial hold on Gilead's $5B cancer drug? It's worse than we were initially told

4 years ago

AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis

4 years ago

Vas Narasimhan reveals a disappointing outlook for Novartis' generics unit, while laying out the pharma's M&A ...

4 years ago

Point unveils new Indy site to shore up supply chain in fight against prostate cancer

4 years ago

PhRMA goes on the offensive, attacking the WHO and putting the EU, UK, Australia and others on notice

4 years ago

Organon launches day-off campaign to encourage business leaders to prioritize women's health

4 years ago

With new buyout, J&J jumps back in on a storied but troubled Holy Grail target

4 years ago

4SC pulls plug on domatinostat; Pharming says leniolisib meets both endpoints

4 years ago

Cash-strapped antibiotics player Entasis could go private with a small-dollar buyout offer on the table

4 years ago

A faster 'protein printer' out of the UK earns new round of funding with plans to expand platform

4 years ago

Carl June: ‘We can now conclude that CAR-T cells can actually cure patients’

4 years ago

Novo surges on upbeat Q4 review and a move to produce Wegovy in-house. But charge of insulin price manipulation ...

4 years ago

FDA slams clinical hold on LogicBio's gene editing drug after clotting cases in child patients

4 years ago

A win in Rett syndrome? Not so fast — biotech shares slide amid concerns of last-minute trial changes

4 years ago

GSK grabs $1.25B cash and a cut of Gilead's megablockbuster Biktarvy sales as HIV rivals settle patent suit

4 years ago

Novartis axes a once 'first-in-class' prospect as another JAK program fails to clear a risk/benefit analysis

4 years ago

FDA takes a rare step and asks Pfizer to submit a Covid-19 vaccine EUA for the youngest children

4 years ago

New buyers lining up bids for Novartis' giant generics arm

4 years ago

First page Previous page 589 590 591592593 594 595 Next page Last page